UK Markets closed
NIKKEI 225
27,819.33 -180.67 (-0.65%) HANG SENG
20,082.43 +471.63 (+2.40%) CRUDE OIL
93.92 +1.99 (+2.16%) GOLD FUTURES
1,802.70 -11.00 (-0.61%) DOW
33,323.44 +13.93 (+0.04%) BTC-GBP
19,819.77 +336.24 (+1.73%)
Esperion Therapeutics, Inc. (ESPR)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 03:23PM EDT. Market open.
| Previous close | 6.41 |
| Open | 6.41 |
| Bid | 6.57 x 1100 |
| Ask | 6.58 x 900 |
| Day's range | 6.40 - 6.64 |
| 52-week range | 3.28 - 14.78 |
| Volume | |
| Avg. volume | 832,351 |
| Market cap | 409.416M |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
- Motley Fool
Esperion Therapeutics (ESPR) Q2 2022 Earnings Call Transcript
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR)Q2 2022 Earnings CallAug 02, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.
- Zacks
Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
